ReviewMicroorganisms2021
Application of Bacteriophages for Mycobacterial Infections, from Diagnosis to Treatment.
Review in Microorganisms, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 35 citations in OpenAlex.
- Endolysin LysSte134_1 Reduces Staphylococcus Bacterial Load in Infected Wounds In Vivo.International journal of molecular sciences · 2026Article
- Functional Annotation of FD Cluster Phage Bouclier that InfectsmicroPublication biology · 2026Article
- Use of the bacteriophage-derived endolysin CHAPK-SH3blys as a potent novel treatment for biofilm-associatedMicrobiology spectrum · 2025Article
- Comparative study on the virulence of mycobacteriophages.Journal of virology · 2025Article
- Genome Sequences of Alatato and Audell, two Phages that infectmicroPublication biology · 2025Article
- Phage therapy for intestinal infections: efficacy, challenges, and future directions in translational research.Frontiers in microbiology · 2025Review
- Complete genome sequences of mycobacteriophages Ashwin from cluster O and Chanagan from cluster A1.Microbiology resource announcements · 2024Article
- Mycobacteriophages and Their Applications.Antibiotics (Basel, Switzerland) · 2024Review
- A Comprehensive Review on Phage Therapy and Phage-Based Drug Development.Antibiotics (Basel, Switzerland) · 2024Review
- Genome sequence of Xenia2 a DV cluster phage that infectsMicrobiology resource announcements · 2024Article
- An Exploratory Review of the Potential of Lytic Proteins and Bacteriophages for the Treatment of Tuberculosis.Microorganisms · 2024Review
- Rapid Diagnosis of Drug-Resistant Tuberculosis-Opportunities and Challenges.Pathogens (Basel, Switzerland) · 2023Review
- Complete genome sequence of Azrael100, a V cluster mycobacteriophage.Microbiology resource announcements · 2023Article
- Compassionate Use of Bacteriophages for Failed Persistent Infections During the First 5 Years of the Israeli Phage Therapy Center.Open forum infectious diseases · 2023Article
- Phage Therapy for Nontuberculous Mycobacteria: Challenges and Opportunities.Pulmonary therapy · 2023Review
- Mycobacteriophages in diagnosis and alternative treatment of mycobacterial infections.Frontiers in microbiology · 2023Review
- Bacteriophages of Mycobacterium tuberculosis, their diversity, and potential therapeutic uses: a review.BMC infectious diseases · 2022Review
- Phascinating Phages.Microorganisms · 2022Review
- Mycobacteriophages: From Petri dish to patient.PLoS pathogens · 2022Review
- Bacteriophage treatment of disseminated cutaneous Mycobacterium chelonae infection.Nature communications · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
Abstract
Mycobacterium tuberculosis and other non-tuberculous mycobacteria are responsible for a variety of different infections affecting millions of patients worldwide. Their diagnosis is often problematic and delayed until late in the course of disease, requiring a high index of suspicion and the combined efforts of clinical and laboratory colleagues. Molecular methods, such as PCR platforms, are available, but expensive, and with limited sensitivity in the case of paucibacillary disease. Treatment of mycobacterial infections is also challenging, typically requiring months of multiple and combined antibiotics, with associated side effects and toxicities. The presence of innate and acquired drug resistance further complicates the picture, with dramatic cases without effective treatment options. Bacteriophages (viruses that infect bacteria) have been used for decades in Eastern Europe for the treatment of common bacterial infections, but there is limited clinical experience of their use in mycobacterial infections. More recently, bacteriophages' clinical utility has been re-visited and their use has been successfully demonstrated both as diagnostic and treatment options. This review will focus specifically on how mycobacteriophages have been used recently in the diagnosis and treatment of different mycobacterial infections, as potential emerging technologies, and as an alternative treatment option.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.